The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
It’s been very interesting seeing market reaction to bloe’s recent news, and I believe it gives a really good indication on where we will get to here on news. I think 500bopd from c-37 or c-30 getting us to 750bood will take us to circa 10p and hitting our ongoing 1,000bopd target at some point will take us somewhere around the 12-13p mark . Based on our current shares in issue...which coincidentally are similar to bloe’s
In truth lth’s who have been here and supported the science and company for years couldn’t give two hoots around resistance or support levels at 10, 12 or 15p this is all about getting approval and moving towards somewhere between 50p - £1 and finally getting our particular justification that our belief and research from years ago deserves
Been like that (one step forward 2 back) for last few years. Apart from Feb 14th when it was 200 steps back
Looks like I was correct in my posts around a week ago when I said as a general rule of thumb oil experts say every 1,000 bopd puts circa £40m on a market cap . £29m market cap for 700bopd is I reckon about right , when infrastructure improves and they’re able to get 1,100bopd out and sold hen you’ll see 15/16p
Sheltie good to hear from you, I’ve thought since the valentine days massacre that there was nothing in the science to justify Iclaprim not being approved and therefore more likely that there are some dark arts at play. I.e. lobbying / backhanders, someone trying to make motif insolvent to Phoenix Iclaprim for themselves etc . If the above is true what’s to stop them ever approving us?! It’s not as if they would have have to face the music or be held to account for another negative decision. the US is as corrupt if not more than most other places
Stockdale no offence mate but a few comments on a board cannot control the share price of any serious company. The company and CH’a performance over the last few years is what you should be focussing on ....I am bemused at why you would expect a market cap of £24m + when the company has spent £50m so far and generated less than 10% of that outlay in revenue, truly shocking performance! even today’s supposed positive news means massive dilution to think about any feasible commercial future..good luck